As shown in Fig. 3F, Supplementary Fig. 15 and Supplementary Table 08, the sensitivity of the BC cell lines to HER2 inhibitors was significantly correlated with the percentage of cells in the cell line expressing ERBB2. This result holds true even when using bulk gene expression of the cell lines (available in the CTRPv2 dataset from the Cancer Cell Line Encyclopaedia—CCLE24), in place of the percentage of cells (Supplementary Fig. 16). Here, ERBB2 is linked to cancer.